Show simple item record

dc.contributor.authorManabe, Yukari C.
dc.contributor.authorWorodria, William
dc.contributor.authorCobelens, Frank
dc.date.accessioned2013-01-04T07:52:32Z
dc.date.available2013-01-04T07:52:32Z
dc.date.issued2012-02-16
dc.identifier.citationMunabe, Y,C., Worodria, W., Cobelens, F. (2012). In reply to `Empirical tuberculosis treatment or improved diagnostics? The International Journal of Tuberculosis and Lung Disease, 16(2)en_US
dc.identifier.issn1027-3719
dc.identifier.urihttp://dx.doi.org/10.5588/ijtld.11.0242
dc.identifier.urihttp://hdl.handle.net/10570/950
dc.description.abstractWe read the article by Lawn and colleagues with great interest. Atypical presentation and limited diagnostic capability in resource-limited settings lead to delays in treatment that could contribute to high rates of antiretroviral therapy (ART) associated TB. To address the potential role of empiric TB treatment in immunosuppressed patients first presenting for care, we proposed the ‘Prevention of early mortality by presumptive TB treatment in HIV-infected patients initiating antiretroviral therapy’ (PROMPT) study, which was funded by the European Developing Country Clinical Trials Programme (EDCTP) in October 2010. We have started enrolling 334 patients from four geographically diverse countries (Gabon, Mozambique, South Africa and Uganda) in a randomised open label clinical trial targeting a population of people with high mortality risk: patients with CD4 T-cell count <50 cells/μl and body mass index (BMI) < 18 kg/m2.en_US
dc.language.isoenen_US
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen_US
dc.subjectTuberculosis (TB)en_US
dc.subjectAntiretroviral therapyen_US
dc.subjectARTen_US
dc.subjectTB-HIV coinfectionen_US
dc.subjectCD4 T-cell count.en_US
dc.titleIn reply to `Empirical tuberculosis treatment or improved diagnostics?'en_US
dc.typeJournal article, peer revieweden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record